Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $0.91 in the prior trading day, CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $0.86, down -5.14%. In other words, the price has decreased by -$5.14 from its previous closing price. On the day, 1.79 million shares were traded. CTMX stock price reached its highest trading level at $0.94 during the session, while it also had its lowest trading level at $0.8405.
Ratios:
Our goal is to gain a better understanding of CTMX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 20 ’24 when Landau Jeffrey B sold 4,181 shares for $1.23 per share. The transaction valued at 5,139 led to the insider holds 119,056 shares of the business.
BELVIN MARCIA sold 4,181 shares of CTMX for $5,139 on Aug 20 ’24. The SVP, Chief Scientific Officer now owns 175,648 shares after completing the transaction at $1.23 per share. On Aug 20 ’24, another insider, ROWLAND LLOYD A, who serves as the General Counsel of the company, sold 4,181 shares for $1.23 each. As a result, the insider received 5,139 and left with 130,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 67553080 and an Enterprise Value of -35775420. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.49. Its current Enterprise Value per Revenue stands at -0.283 whereas that against EBITDA is -4.184.
Stock Price History:
Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -22.45%, while the 200-Day Moving Average is calculated to be -46.03%.
Shares Statistics:
The stock has traded on average 780.28K shares per day over the past 3-months and 1322110 shares per day over the last 10 days, according to various share statistics. A total of 78.26M shares are outstanding, with a floating share count of 76.93M. Insiders hold about 1.69% of the company’s shares, while institutions hold 72.41% stake in the company. Shares short for CTMX as of 1730332800 were 5666225 with a Short Ratio of 7.26, compared to 1727654400 on 6249942. Therefore, it implies a Short% of Shares Outstanding of 5666225 and a Short% of Float of 7.3.
